Submitted:
11 November 2026
Posted:
12 November 2026
You are already at the latest version
Abstract
Background: Cardiohepatic syndrome reflects bidirectional heart-liver interactions, particularly in heart failure with elevated right-sided pressures and venous congestion. Congestive hepatopathy may impair hepatic function and influence cardiovascular drug disposition. Whether congestion alters drug exposure remains uncertain. Objective: To review cardiohepatic interactions and propose a congestion-phenotyping framework. Methods: This narrative review examines venous congestion, congestive hepatopathy, liver stiffness measurement (LSM), venous excess ultrasound (VExUS), hepatic biomarkers, hemodynamics, and cardiovascular pharmacotherapy. Results: Elevated right-sided pressures and venous congestion cause hepatic hemodynamic stress and may produce congestive hepatopathy. Hepatic dysfunction can alter the disposition of cardiovascular medications. VExUS and LSM offer complementary assessments of systemic venous congestion and hepatic stiffness, but neither independently establishes fibrosis or guides drug dosing. Congestion-related changes in hepatic and renal function, protein binding, gastrointestinal absorption, and volume of distribution may affect cardiovascular drug pharmacokinetics (PK) and pharmacodynamics (PD). However, evidence linking quantified congestion to drug exposure or PD response remains limited. No prospective evidence validates VExUS- or LSM-guided dosing based on drug concentrations or established PK/PD targets. We propose a physiology-informed framework for incorporating congestion assessment into pharmacological decisions during decongestion. Conclusion: Cardiohepatic assessment should distinguish established hemodynamic effects from the unproven relationship between congestion and drug exposure. Combining clinical evaluation, biomarkers, venous ultrasound, LSM, and selected invasive hemodynamics may improve congestion phenotyping and monitoring. This framework remains hypothesis-generating, not a validated dosing strategy. Prospective studies integrating congestion measures, drug concentrations, PK/PD parameters, and outcomes are needed to determine whether congestion-informed pharmacotherapy improves safety and effectiveness.
Keywords:
cardiohepatic syndrome
; hepatic congestion
; cardiovascular pharmacokinetics
; heart failure
; acute coronary syndrome
; venous excess ultrasound
; guideline-directed medical therapy
; liver stiffness measurement
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.